Merck & Co. said Monday that its third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges. It still beat Wall Street's ...
Oct 28, 2013
0
0
(Medical Xpress)—People given a choice between generic or branded drugs should look closely at the ingredients in the drug they are buying, argue economists from Deakin University's Graduate School of Business.
Sep 16, 2013
0
0
Coverage under President Barack Obama's health care law won't be cheap, but two independent private studies show that cost-conscious consumers hunting for lower premiums will have plenty of options.
Sep 4, 2013
0
0
Spanish researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have found that during the early stages of mammalian development, embryonic cells embark on a battle for survival. Through this battle, ...
Jul 11, 2013
0
0
New potentially life-saving HIV drugs are "beyond reach" due to restrictive patents, Doctors Without Borders (MSF) said Tuesday, even though basic medication for the disease has become cheaper.
Jul 2, 2013
2
0
British drugmaker AstraZeneca PLC plans to spend about $260 million on Omthera Pharmaceuticals Inc., a specialty drug developer with only 14 employees but has a potential treatment for patients who have high levels of fats ...
May 28, 2013
0
0
(AP)—French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.
May 2, 2013
0
0
(AP)—The Obama administration appealed a federal judge's order to lift all age limits on who can buy morning-after birth control pills without a prescription. In appealing the ruling on Wednesday, the administration recommitted ...
May 2, 2013
0
0
Pfizer Inc.'s first-quarter net income rose 53 percent despite falling sales, mainly because the world's second-largest drugmaker took big charges a year ago. Pfizer's results fell short of Wall Street's expectations, and ...
Apr 30, 2013
0
0
Britain's competition watchdog accused GlaxoSmithKline on Friday of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat.
Apr 19, 2013
1
0
